PIM1 and plasma cell myeloma: PIM1 could be targeted with the PIM kinase inhibitors that have already shown activity in myeloma and acute myeloid leukemia.49, 50 However, some of the non-recurrent alterations could have been randomly acquired and may not be causally related to the pathogenesis of the disease.